Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News information

Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement

2022-07-01
|
Page View:

On June 28, 2022, Shanghai Medicilon Inc. (“Medicilon”) and Shanghai BravoBio Co., Ltd (“BravoBio”) held an online ceremony for signing the Strategic Cooperation Agreement, which marks the two companies have officially become cooperative partners.

With the outstanding performance of vaccine industry during COVID-19 pandemic and the support of government policies, novel vaccines are gradually emerging, pushing the vaccine R&D into a fast track. BravoBio, as a council member of China Association for Vaccines (CAV), is committed to the R&D and industrialization of a number of blockbuster vaccines, including novel COVID-19 Vaccine, multi-valent Rotavirus Vaccine, next-generation Pneumococcal Conjugate Vaccine, broad-spectrum Human Papillomavirus Vaccine (HPV) and Varicella-zoster Virus Vaccine (VZV). Its partner, Medicilon, is an integrated contract research organization (CRO), and has extensive practical experience in providing preclinical research for innovative vaccines. The strengths of the two companies are perfectly complementary, laying a solid foundation for broader strategic partnership.

medicilon and BravoBio.jpg

Under the context, in order to further the progress of preclinical research of its innovative vaccine pipeline, BravoBio is willing to reach a strategic cooperation with Medicilon. Under this Agreement, Medicilon will utilize its one-stop preclinical platform to provide the services of drug discovery, pharmaceutical research, preclinical research and other integrated technical platforms, to help BravoBio’s innovative vaccines move into clinical stage at the fastest speed possible. The two companies will leverage their strengths to form a deeper collaboration.

Dr. Ke Wu, CEO of BravoBio, said, “As a leading CRO in China, Medicilon provides a good variety of services covering the territory that BravoBio is seeking for high-level partners. We’re delighted to establish a strategic partnership with Medicilon, and recently we have entered into an agreement with Medicilon regarding one of our blockbuster vaccines. The two companies will make concerted efforts to push this project into clinical stage quickly and benefit all mankind at an early date!”

Dr.  Chunlin Chen, founder and CEO of Medicilon, said, “Under the leadership of Dr. Wu, BravoBio has good existence in vaccine industry and boasts a comprehensive pipeline and innovative technologies. We are very pleased to reach a strategic partnership with BravoBio. Medicilon will leverage our one-stop preclinical platform to enpower the preclinical research of BravoBio’s innovative vaccines. In return this collaboration will further enhance our expertise in vaccine R&D field while enabling our partners to meet the growing demands of vaccine development.”

About BravoBio

Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to North Shanghai Biopharma Park in October 2021. Its subsidiary company, BravoVax, is a “state level high-tech enterprise” and a council member of China Association for Vaccines (CAV). It was awarded as “China Rising Star” by Deloitte in 2020, becoming the only vaccine company to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), conjugation of polysaccharide and protein, novel adjuvant, new process and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people’s lives, aiming for a healthier and happier future.

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. Based on key links of drug R&D, we focus on the demand for innovation and the development of the global pharmaceutical industry. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

分享到:
Relevant newsRelevant news